(Reuters) - Not including the generic Norvasc contribution "will be viewed as a disappointment," Cowen & Co. analyst Ken Cacciatore said in a research note.
Mylan's shares slipped nearly 3 percent early, despite the fact that the company's results beat its prior forecast.
Read more at Reuters.com Hot Stocks News
Mylan's shares slipped nearly 3 percent early, despite the fact that the company's results beat its prior forecast.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment